XAIR - מחיר רכישת החברה beyondair.net

Beyond Air, Inc. (XAIR) is deploying compact LungFit systems, replacing heavy cylinders with air-to-gas generation for lung therapy. However, marketing costs for the new systems are weighing on profitability, while the inertia of US clinics necessitates rigorous management. Diversification of medical devices protects profits from tariff changes. The market dynamics reflected in the price action show an Enterprise Value of 13.15, confirming the scale of the business.

Enterprise Value (EV) represents the sum of market capitalization and net debt, reflecting the actual cost of a full business buyout. Investors utilize this total market value assessment to analyze asset resilience against macroeconomic shocks. A decline in this metric may signal a crisis, while a sharp increase suggests overvaluation. For Beyond Air, Inc. (XAIR), steady demand for nitric oxide delivery systems smooths the volatility of this indicator. The non-cyclical nature of pulmonary hypertension therapy provides fundamental support for the company's value.